So proud of my @UNGlobalPulse team and collaborators that step by step and over the years have managed to bring 🤖 science closer to humanitarian and development work. We now have a library!! 📚 📚📚 https://t.co/rOxXQRllo5 Some peer-reviewed highlights in this thread 👇
More from Science
https://t.co/Xe5xFdtDfO
https://t.co/e3RBxj0ly3
1. Monkey Outrage!
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) August 17, 2020
The worst treatment was kept for the monkeys. The macaques breed of monkeys are small, relatively light primates, which are often used for animal experiments at LPT. \u2018They are kept in cramped conditions in small cages. https://t.co/6D0yisjd9B
https://t.co/cJlCMqyP2v
11. Max Planck Monkey Photos (2) pic.twitter.com/0yE9D6iswp
— Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193 (@BillyBostickson) August 17, 2020
https://t.co/5n5TK67iKB
😭
The new answer to a 77-year-old problem in data analysis, published today in @naturemethods. Instead of significance tests, use estimation graphics. Our software suite DABEST makes it easy for everyone to visualize effect sizes.https://t.co/UzwXJ7EUC5 pic.twitter.com/VtxyY0xaRM
— Adam Claridge-Chang (@adamcchang) June 19, 2019
https://t.co/hm9NoaU4nr
Open letter to journal editors: dynamite plots must die. Dynamite plots, also known as bar and line graphs, hide important information. Editors should require authors to show readers the data and avoid these plots. https://t.co/0GNKEIUCJL pic.twitter.com/OS9ytEFRZN
— Rafael Irizarry (@rafalab) February 22, 2019
https://t.co/8fKDiKjSWc
Couldn't find D3 code for grouped horisontal box plots that show data points so I made this @mbostock @thisisalfie https://t.co/cQjDPhyZdw pic.twitter.com/y6RNmDB2p3
— Ulrik Lyngs (@ulyngs) June 28, 2017
https://t.co/jkaicC1F2x
made a pkg for pirate plots in ggplot: add any of points/means/bars/CIs/violins \u2013 better than ye olde bar/box plotshttps://t.co/Z2m2kW3hsl pic.twitter.com/npAirPQexM
— Mika Braginsky (@mbraginsky) September 28, 2017
https://t.co/PpxWT4Jef4
See the new #PowerBI visual awesomeness for data points & sources, box-&-whisker plots! https://t.co/dOmgoxWfDE pic.twitter.com/HAUOAMJEJW
— Microsoft Power BI (@MSPowerBI) February 1, 2016
A thread on the potential near term catalysts behind why I have increased my position in 4d Pharma @4dpharmaplc (LON: #DDDD):
1) NASDAQ listing. This is the most obvious.
The idea behind this is that the huge pool of capital and institutional interest in the NASDAQ will enable a higher per-share valuation for #DDDD than was achievable in the UK.
Comparators to @4dpharmaplc #DDDD (market capitalisation £150m) on the NASDAQ and their market capitalisation:
Seres Therapeutics: $2.33bn = £1.72bn (has had a successful phase 3 C. difficile trial); from my previous research (below) the chance of #DDDD achieving this at least once is at least
While looking at speculative pharmaceutical stocks I am reminded of why I am averse to these risky picks.#DDDD was compelling enough, though, to break this rule. The 10+ treatments under trial, industry-leading IP portfolio, and comparable undervaluation are inescapable.
— Shrey Srivastava (@BlogShrey) December 16, 2020
Kaleido Biosciences: $347m = £256m. 4 products under consideration, compared to #DDDD's potential 16. When you view @4dpharmaplc's 1000+ patents and AI-driven MicroRx platform (not to mention their end-to-end manufacturing capability), 4d's undervaluation is clear.